Metformin is thought to have an anorexic effect partly by promoting the secretion of GLP-1 and activating afferent inputs from the intestinal tract to the NTS [24], but there is currently no evidence that the degree of weight loss exceeds 5%, which is the standard for use as an anti-obesity drug
This isnt something you should ever manage on your own
If a patient is switching from a different medication class, such as metformin, there are washout periods and metabolic stabilisation windows we assess individually
Men with 20 pack-years had an aHR of 1.29 (95% CI 1.181.42), while women with 10 pack-years had an aHR of 1.75 (95% CI 1.122.73) for MASLD with significant fibrosis [60]
doi:10.1016/j.bbi.2014.04.001 22
"As use of this medication is extended and expanded for weight loss and other health advocacy, there is an opportunity to do much more, including product development, packaging, online and in-store merchandising, education, and promotion." Opportunities include: Merchandise dietary and nutritional support items near the pharmacy in drug and grocery, improving the shopping experience for consumers taking GLP-1s Understand that 91% of Millennials, 90% of Gen Z, and 64% of Gen X on GLP-1 medications are interested in packaged foods that support their weight loss goals, and they want messaging called out on the package Meet consumers where they are with product and health information, amplifying digital commerce programming Advance opportunities on retailer apps and websites to support these shoppers Acosta Group's "GLP-1 & The Weight Loss Revolution Shopper Insights Study" was conducted Feb
